Humacyte, Inc.
Clinical trials sponsored by Humacyte, Inc., explained in plain language.
A biotech company developing bioengineered human tissues and organs.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Lab-Made blood vessel could free dialysis patients from catheters Results expected Jun 2027 (estimated) May already have reported ↗
-
Lab-Grown vessels could revolutionize dialysis access
Disease control CompletedThis trial is testing whether a lab-grown human blood vessel (called a Human Acellular Vessel) can serve as a better connection point for hemodialysis than the standard synthetic grafts. People with end-stage kidney disease who need dialysis often require a reliable access point …
Phase 3 • Sponsor: Humacyte, Inc. • Aim: Disease control
Last updated Aug 21, 2026 00:00 UTC
-
Lab-Grown blood vessels could save limbs after trauma
Disease control CompletedThis trial is testing whether a lab-grown blood vessel made from human collagen can safely replace damaged arteries in people with life- or limb-threatening vascular injuries below the neck. Participants receive the artificial vessel as a bypass or replacement during emergency su…
Phase 2/3 • Sponsor: Humacyte, Inc. • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
Engineered blood vessel could simplify dialysis for kidney patients
Disease control CompletedThis phase 3 trial tested a lab-grown blood vessel (Human Acellular Vessel, or HAV) against the standard surgically created fistula in 242 people with end-stage kidney disease on hemodialysis. The goal was to see which option works better for providing reliable access to filter b…
Phase 3 • Sponsor: Humacyte, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC